Hill-Rom Holdings, Inc. (NYSE:HRC) SVP Mary Kay Ladone sold 3,125 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.00, for a total transaction of $331,250.00. Following the completion of the transaction, the senior vice president now directly owns 13,566 shares in the company, valued at approximately $1,437,996. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
NYSE HRC opened at $108.21 on Wednesday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.22 and a current ratio of 1.52. The company has a market capitalization of $7.17 billion, a price-to-earnings ratio of 49.64, a price-to-earnings-growth ratio of 1.26 and a beta of 0.70. The company’s 50-day simple moving average is $100.58 and its two-hundred day simple moving average is $105.04. Hill-Rom Holdings, Inc. has a one year low of $72.29 and a one year high of $117.50.
Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, May 1st. The medical technology company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.15 by $0.13. Hill-Rom had a net margin of 5.04% and a return on equity of 22.60%. The business had revenue of $723.20 million for the quarter, compared to analysts’ expectations of $701.72 million. During the same period last year, the business earned $1.14 EPS. The company’s revenue was up 1.3% compared to the same quarter last year. Equities analysts expect that Hill-Rom Holdings, Inc. will post 5.45 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in HRC. BDO Wealth Advisors LLC acquired a new stake in Hill-Rom in the 1st quarter worth approximately $29,000. Signaturefd LLC lifted its stake in Hill-Rom by 53.3% during the 1st quarter. Signaturefd LLC now owns 302 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 105 shares during the period. CWM Advisors LLC acquired a new stake in Hill-Rom during the 1st quarter valued at approximately $39,000. Lloyd Advisory Services LLC. acquired a new stake in Hill-Rom during the 4th quarter valued at approximately $41,000. Finally, Optimum Investment Advisors acquired a new stake in Hill-Rom during the 1st quarter valued at approximately $50,000. Institutional investors and hedge funds own 85.68% of the company’s stock.
Several research analysts recently commented on the stock. Morgan Stanley reduced their price target on shares of Hill-Rom from $138.00 to $125.00 and set an “overweight” rating on the stock in a research note on Friday, March 27th. Barclays reaffirmed a “buy” rating and issued a $125.00 price target on shares of Hill-Rom in a research note on Tuesday, April 14th. Finally, UBS Group reduced their price target on shares of Hill-Rom from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Monday, May 4th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $126.20.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
See Also: How is inflation measured?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.